The researchers further administered standard-dose (0.16 mg/kg/day) ATO monotherapy to a non-APL AML patient carrying an ATO-sensitive p53 mutation, observing the effective restoration of p53 transcriptional regulatory function accompanied by the significant clearance of minimal residual disease (MRD) [44]. This evidence concerns the gene TP53 and acute myeloid leukemia.